<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3436">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04442958</url>
  </required_header>
  <id_info>
    <org_study_id>2020.05.2.14.070</org_study_id>
    <nct_id>NCT04442958</nct_id>
  </id_info>
  <brief_title>Effectiveness of Convalescent Immune Plasma Therapy</brief_title>
  <official_title>Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bagcilar Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bagcilar Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the safety, improvement of clinical symptoms and
      laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients
      with ARDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate the safety, improvement of clinical symptoms with
      hypoxemia, metabolic and laboratory parameters of patients with convalescent immune plasma
      treatment in severe Covid-19 patients followed up in critical care unit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Actual">June 17, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma ferritin level</measure>
    <time_frame>7. day</time_frame>
    <description>Acute phase reactant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphocyte count</measure>
    <time_frame>7. day</time_frame>
    <description>Infection markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>D-Dimer level</measure>
    <time_frame>7. day</time_frame>
    <description>Hypercoagulability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-Reactive protein level</measure>
    <time_frame>7. day</time_frame>
    <description>Infection markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma procalcitonin level</measure>
    <time_frame>7. day</time_frame>
    <description>Infection markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma fibrinogen level</measure>
    <time_frame>7. day</time_frame>
    <description>Coagulopathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fractional Inspired Oxygen Level</measure>
    <time_frame>7. day</time_frame>
    <description>Arterial oxygenation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Oxygen Saturation level</measure>
    <time_frame>7. day</time_frame>
    <description>Arterial oxygenation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Oxygen level</measure>
    <time_frame>7. day</time_frame>
    <description>Arterial oxygenation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Convalescent Plasma Therapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of 200 mL of convalescent 覺mmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Plasma Therapy Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standart critical care treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Convalescent Immune Plasma</intervention_name>
    <description>One dose of 200 mL of convalescent 覺mmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.</description>
    <arm_group_label>Convalescent Plasma Therapy Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Clinical diagnosis of Covid-19

        Exclusion Criteria Age lower than 18 Lower plasma IgA levels PaO2/FiO2 higher than 300 mmHg
        SpO2 higher than 90
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salih SS Sevdi, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul Bagc覺lar Training and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istanbul Bagc覺lar Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34375</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

